Klaviyo, Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
KVYO$20.43-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited)
| Series A Common Stock · Series B Common Stock · Additional Paid-In Capital · Total Stockholders’ Equity | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Shares · $0.001 Par Value · Number of Shares · $0.001 Par Value · Accumulated Deficit | ||||||||||||||||
| Balance as of June 30, 2024 | 72,510,738 | $73 | 194,081,029 | $194 | $1,796,100 | $(816,867) | $979,500 | |||||||||
| Issuance of common stock upon exercise of common stock options | — | — | 706,906 | 1 | 1,539 | — | 1,540 | |||||||||
| Issuance of common stock upon vesting of restricted stock units | 483,175 | — | 1,225,134 | 1 | (1) | — | — | |||||||||
| Issuance of common stock upon exercise of collaboration agreement warrants | — | — | 344,384 | — | 3 | — | 3 | |||||||||
| Vested warrants related to collaboration agreement | — | — | — | — | 8,100 | — | 8,100 | |||||||||
| Stock-based compensation expense | — | — | — | — | 32,438 | — | 32,438 | |||||||||
| Tax withholdings on settlement of stock-based awards | (28,017) | — | (148,896) | — | (5,495) | — | (5,495) | |||||||||
| Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards | 5,512,369 | 5 | (5,512,369) | (5) | — | — | — | |||||||||
| Net loss | — | — | — | — | — | (1,345) | (1,345) | |||||||||
| Balance as of September 30, 2024 | 78,478,265 | $78 | 190,696,188 | $191 | $1,832,684 | $(818,212) | $1,014,741 | |||||||||
| Balance as of June 30, 2025 | 116,877,930 | $117 | 182,757,254 | $183 | $1,980,007 | $(883,555) | $1,096,752 | |||||||||
| Issuance of common stock upon exercise of common stock options | — | — | 160,120 | — | 267 | — | 267 | |||||||||
| Issuance of common stock upon vesting of restricted stock units | 1,258,799 | 1 | 648,665 | 1 | (2) | — | — | |||||||||
| Issuance of common stock upon exercise of collaboration agreement warrants | — | — | 344,383 | — | 3 | — | 3 | |||||||||
| Vested warrants related to the collaboration agreement | — | — | — | — | 8,100 | — | 8,100 | |||||||||
| Stock-based compensation expense | — | — | — | — | 41,485 | — | 41,485 | |||||||||
| Tax withholdings on settlement of stock-based awards | (66,873) | — | (70,885) | — | (4,107) | — | (4,107) | |||||||||
| Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards | 19,275,341 | 19 | (19,275,341) | (19) | — | — | — | |||||||||
| Net loss | — | — | — | — | — | (426) | (426) | |||||||||
| Balance as of September 30, 2025 | 137,345,197 | $137 | 164,564,196 | $165 | $2,025,753 | $(883,981) | $1,142,074 | |||||||||
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) (cont.)
| Series A Common Stock · Series B Common Stock · Additional Paid-In Capital · Total Stockholders’ Equity | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Shares · $0.001 Par Value · Number of Shares · $0.001 Par Value · Accumulated Deficit | ||||||||||||
| Balance as of January 1, 2024 | 40,841,834 | $41 | 218,524,009 | $219 | $1,713,560 | $(799,043) | $914,777 | |||||
| Issuance of common stock upon exercise of common stock options | — | — | 5,091,283 | 5 | 6,212 | — | 6,217 | |||||
| Issuance of common stock upon vesting of restricted stock units | 805,702 | 1 | 3,325,308 | 3 | (4) | — | — | |||||
| Issuance of common stock upon exercise of collaboration agreement warrants | — | — | 1,033,147 | — | 10 | — | 10 | |||||
| Issuance of common stock under the employee stock purchase plan | 206,156 | — | — | — | 4,362 | — | 4,362 | |||||
| Vested warrants related to collaboration agreement | — | — | — | — | 24,300 | — | 24,300 | |||||
| Stock-based compensation expense | — | — | — | — | 103,508 | — | 103,508 | |||||
| Tax withholdings on settlement of stock-based awards | (71,202) | — | (581,784) | — | (19,264) | — | (19,264) | |||||
| Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards | 36,695,775 | 36 | (36,695,775) | (36) | — | — | — | |||||
| Net loss | — | — | — | — | — | (19,169) | (19,169) | |||||
| Balance as of September 30, 2024 | 78,478,265 | $78 | 190,696,188 | $191 | $1,832,684 | $(818,212) | $1,014,741 | |||||
| Balance as of January 1, 2025 | 88,956,301 | $89 | 183,801,332 | $184 | $1,878,899 | $(845,185) | $1,033,987 | |||||
| Issuance of common stock upon exercise of common stock options | — | — | 22,744,929 | 23 | 1,709 | — | 1,732 | |||||
| Issuance of common stock upon vesting of restricted stock units | 3,357,508 | 3 | 2,104,777 | 3 | (6) | — | — | |||||
| Issuance of common stock upon exercise of collaboration agreement warrants | — | — | 1,033,147 | — | 10 | — | 10 | |||||
| Issuance of common stock under the employee stock purchase plan | 275,800 | — | — | — | 6,093 | — | 6,093 | |||||
| Vested warrants related to the collaboration agreement | — | — | — | — | 24,300 | — | 24,300 | |||||
| Stock-based compensation expense | — | — | — | — | 127,803 | — | 127,803 | |||||
| Tax withholdings on settlement of stock-based awards | (183,532) | — | (180,869) | — | (13,055) | — | (13,055) | |||||
| Conversion of Series B common stock to Series A common stock upon shareholder election and vesting of certain equity awards | 44,939,120 | 45 | (44,939,120) | (45) | — | — | — | |||||
| Net loss | — | — | — | — | — | (38,796) | (38,796) | |||||
| Balance as of September 30, 2025 | 137,345,197 | $137 | 164,564,196 | $165 | $2,025,753 | $(883,981) | $1,142,074 | |||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.